| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| fennel essential oil has major constituents commonly include trans-anethole, fenchone, estragole, limonene, and cis-anethole, and the proportions vary substantially by source, geography, and chemotype. One composition study found trans-anethole ranging 34.8–82.0%, fenchone 1.6–22.8%, estragole 2.4–17.0%, and limonene 0.8–16.5%. Another study found even wider variation, with estragole(toxic) reported up to 66% in some fennel oils. Fennel Oil — Fennel oil is a volatile essential oil distilled mainly from the fruits or seeds of Foeniculum vulgare, with trans-anethole, fenchone, estragole, limonene, α-pinene, and related monoterpenes/phenylpropanoids as variable constituents. It is best classified as a phytochemical essential-oil mixture rather than a single-agent drug. Standard abbreviations include FEO, FVEO, and FVPEO when referring to Foeniculum vulgare subsp. piperitum essential oil. The oncology-relevant identity is highly chemotype-dependent: anethole-rich oils may show weak-to-moderate cytotoxic and anti-inflammatory effects, whereas estragole-rich oils introduce a major genotoxic-carcinogenic safety constraint. Primary mechanisms (ranked):
Bioavailability / PK relevance: Fennel oil is a lipophilic volatile mixture with batch-dependent composition and uncertain systemic exposure after dietary or medicinal use. Oral systemic relevance is constrained by first-pass metabolism, variable absorption, tissue partitioning, and safety limits driven mainly by estragole content. Essential-oil composition should be specified before interpreting any mechanism claim. In-vitro vs systemic exposure relevance: Common anticancer in-vitro concentrations are often high relative to plausible safe systemic exposures. Reported cytotoxic IC50 values for fennel oil are generally in the tens to hundreds of mg/L or µg/mL range, which should be treated as pharmacologically high and not directly translatable to oral use. This is concentration-driven and chemotype-dependent. Clinical evidence status: Oncology evidence is preclinical only. Fennel oil has in-vitro cancer-cell cytotoxicity data and limited animal or extract-based anticancer evidence, but no established cancer RCT evidence and no regulatory approval as an anticancer therapy. Traditional medicinal use exists for non-oncology indications, but the essential oil has an unfavorable or constrained benefit-risk profile where estragole exposure is significant. Fennel Oil Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 6402- | ANE, | FEO, | trans-Anethole of Fennel Oil is a Selective and Nonelectrophilic Agonist of the TRPA1 Ion Channel |
| - | in-vitro, | Nor, | HEK293 |
| 6428- | FEO, | Eug, | Triggering of apoptosis and cell cycle arrest by fennel and clove oils in Caco-2 cells: the role of combination |
| - | in-vitro, | Colon, | Caco-2 |
| 6430- | FEO, | Foeniculum vulgare: A comprehensive review of its traditional use, phytochemistry, pharmacology, and safety |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:404 Target#:1114 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid